A detailed history of Truist Financial Corp transactions in Novo Cure LTD stock. As of the latest transaction made, Truist Financial Corp holds 11,422 shares of NVCR stock, worth $242,260. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,422
Holding current value
$242,260
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 31, 2025

BUY
$14.54 - $33.41 $166,075 - $381,609
11,422 New
11,422 $340,000
Q2 2023

Aug 01, 2023

BUY
$40.29 - $82.51 $141,095 - $288,950
3,502 Added 38.33%
12,638 $524,000
Q1 2023

May 05, 2023

SELL
$56.44 - $118.81 $137,882 - $290,252
-2,443 Reduced 21.1%
9,136 $549,000
Q4 2022

Feb 17, 2023

BUY
$63.98 - $85.37 $41,395 - $55,234
647 Added 5.92%
11,579 $849,000
Q3 2022

Oct 26, 2022

BUY
$67.99 - $89.57 $104,024 - $137,042
1,530 Added 16.27%
10,932 $831,000
Q2 2022

Jul 22, 2022

BUY
$56.6 - $89.9 $532,153 - $845,239
9,402 New
9,402 $653,000
Q1 2021

May 17, 2021

SELL
$124.11 - $190.17 $247,351 - $379,008
-1,993 Closed
0 $0
Q4 2020

Nov 19, 2021

SELL
$112.16 - $174.14 $410,056 - $636,655
-3,656 Reduced 64.72%
1,993 $345,000
Q4 2020

Feb 18, 2021

BUY
$112.16 - $174.14 $423,628 - $657,726
3,777 Added 201.76%
5,649 $978,000
Q3 2020

Nov 13, 2020

BUY
$58.05 - $111.31 $108,669 - $208,372
1,872 New
1,872 $208,000
Q2 2020

Aug 14, 2020

SELL
$57.2 - $74.41 $310,710 - $404,195
-5,432 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$57.05 - $95.75 $201,957 - $338,955
-3,540 Reduced 39.46%
5,432 $365,000
Q4 2019

Feb 14, 2020

BUY
$68.3 - $93.8 $612,787 - $841,573
8,972 New
8,972 $756,000

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $2.23B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Truist Financial Corp Portfolio

Follow Truist Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Truist Financial Corp with notifications on news.